Responsible for the evaluation, analysis and development of new business opportunities for Mayo Clinic. This includes, but is not limited to partnerships, joint ventures, new company spin-offs, mergers and acquisitions. In addition, this position evaluates the commercial potential of a variety of inventions/discoveries, and then identifies, develops and helps source new technology commercialization opportunities.

- Lead the strategy and execution of revenue growth through business development opportunities by building deal flow related to Recombinetics’ genetically editing technology of TALENS and CRISPR leading to $3M the last calendar year.This role works in a collaborative manner with internal General Manager of each Division along with key researchers to drive deal flow to increase revenue targets through partnership and joint venture agreements with high tech strategic targets. This includes establishing their successful Key Opinion Leadership Strategy used to secure Development Agreement Sales for our Cardiovascular and Cancer Models totaling $3M in revenue the last calendar year of work.

- Lead the execution of VBOX’ strategic planning and marketing activities as well as all business development alliances including the ultimate successful sale of VBOX to a strategic partner.• Directed the strategic plan process which focused on strategic marketing, business and product development strategies that fit the goals of the Board of Directors. This plan was the blueprint of for the ultimate successful sale of the company to a strategic partner.• Management of VBOX Business Development activities including: product line extensions, distribution agreement negotiations, identification and exploration of strategic partnerships and development agreements and ultimately managing the sale of VBOX: from identifying potential acquirers, negotiating terms through due diligence and close. • Responsible for developing various market models for Oxygen Therapy opportunities. This includes in---depth market research and the creation of financial models relating to market and penetration projection of VBOX’ product line portfolio.• Responsible for all product development activities ranging from prototype design verification to subsequent launch of our product to our regulatory strategy and implementation. This includes a successful approval of the Trooper by the FDA and passing in December of 2013 of an FDA Audit inspection for our manufacturing facility in White Bear Lake, MN.• Responsible for full P&L activities including managing all expenses relating to the daily operations of the company, budget planning and leading two successful rounds of financing netting the company $9.8M in cash.

- Reporting directly to the CEO and a member of Haemonetics Operating Committee, a select group chosen by the CEO to oversee operations at Haemonetics. Lead the successful identification, due diligence and acquisition of Business Development targets resulting in $172M in additional revenue.• Identified and explored key market and license opportunities for Arryx Holographic Optical Trapping technology. Organized and implemented first long range strategic plan that included market research, research and development, regulatory planning and advanced manufacturing for the first base platform. License opportunities included agreements with Abbott and Invitrogen Inc.• Restructured Arryx Clinical and R&D activities to high priority projects in order to maximize speed to market. Results of this delivered first commercial product launch using holographic optical trapping technology for infectious disease detection in blood.• Delivered first demonstration device within 10 months of Arryx acquisition. Demonstration device will be the foundation platform for all products related to blood screening using antibody measurement for a wide variety of diagnostic applications. This platform will be disruptive to current devices in portability, ease of use and time to results while greatly increasing value to healthcare provider.

Vice President Business Development and Strategic Planning 2003 – 2006• Introduced and developed long-­‐range strategic planning process resulting in Haemonetics first corporate strategic plan which was presented and accepted by the Board of Directors. This process included working closely with the CEO to determine and communicate the Company’s mission, vision and subsequent strategies and tactics. In addition, this function included working closely with each Division President to identify core business growth and plan for growth beyond current business portfolio through gap analysis and business development strategies.• Identified and explored strategic partnerships, joint ventures, distribution agreements, and technology acquisitions that are consistent with the Haemonetics’s strategy and core competencies, with the objective to improve the revenue and earnings growth profile. Lead negotiations and due diligence activities that resulted in the following successful closings; acquisition of IDM Inc., Equity, Development and Stock Acquisition of Arryx, Inc., Bloodstream product line, Zimmer distribution agreement, ZLB exclusive supply agreement and license/distribution agreement of the platelet rich protein product line from Cascade Medical.

• Managed acquisition and license process for the company’s M&A activities highlighted by the successful sale of company. Activities included managing and overseeing all activities including negotiations, due diligence process and pre closing activities (Hart Scott Rodino filings, proxy statements, shareholder voting, and various precedent closing requirements.) No investment bank was retained for this acquisition

- Managed corporate long-range strategic planning and annual operating planning process. This included working with senior management of various St. Jude Division’s to determine and consolidate their strategies and tactics into the overall corporate mission. Evaluated and managed the analysis of select medical device markets and potential target acquisitions relative and to St. Jude’s mergers and acquisitions strategies and corporate development activities.